

PATENT NUMBER

U.S. OFFICE PATENT ATTORNEY

O.P.E. 1	PATENT DATE
-------------	-------------

APPLICANTS

Rostyslav Stoika
Gregory Horwitz
Xun Zhang
Shlomo Melmed

modulating activation of lymphocytes and screening potential immunomodulating agents by targeting pituitary tumor transforming gene (PTTG) expression and/or function

PTO-2040
12/89[illegible]

<input type="checkbox"/> TERMINAL DISCLAIMER	DRAWINGS			CLAIMS ALLOWED	
	Sheets Drwg.	Figs. Drwg.	Print Fig.	Total Claims	Print Claim for O.G.
<input type="checkbox"/> a) The term of this patent subsequent to _____ (date) has been disclaimed.	_____ (Assistant Examiner) (Date)			NOTICE OF ALLOWANCE MAILED	
	_____ (Primary Examiner) (Date)			ISSUE FEE	
Amount Due				Date Paid	
<input type="checkbox"/> b) The term of this patent shall not extend beyond the expiration date of U.S Patent. No. _____ _____ _____	_____ (Legal Instruments Examiner) (Date)			ISSUE BATCH NUMBER	
<input type="checkbox"/> c) The terminal _____ months of this patent have been disclaimed.					

WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.

Form **PTO-436A**
(Rev. 6/98)

(LABEL AREA)

Best Available Copy